FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
SALT LAKE CITY, April 06, 2016 -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at Needham & Company’s 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. ET.
A live audio webcast of the presentation will be available via the "Investor Relations" page of the Lipocine website, www.lipocine.com. Please log on through Lipocine's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on Lipocine's website for 90 days following the presentation.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. LPCN 1021, an oral testosterone replacement therapy product candidate, demonstrated positive efficacy and safety results in Phase 3 testing and has a New Drug Application under review with the FDA. LPCN 1111, a next-generation oral testosterone replacement therapy product with once-daily dosing, is currently in Phase 2 testing. LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth, is currently in Phase 1 testing and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains “forward looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts relating to Lipocine’s common stock, the FDA review process relating to our product candidates and the possible outcome of such process, clinical trials, the potential uses and benefits of our product candidates, product development and commercialization efforts and the projected timing and outcome of regulatory filings and actions. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to our products, expected product benefits, clinical and regulatory expectations and plans, regulatory developments and requirements, risks related to the FDA’s review of our NDA for LPCN 1021, the receipt of regulatory approvals, the results of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, the risks related to market conditions for Lipocine’s common stock and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
CONTACT: Morgan Brown Executive Vice President & Chief Financial Officer Phone: (801) 994-7383 [email protected] Investors: John Woolford Phone: (443) 213-0500 [email protected] Media: Heather Anderson Phone: (980) 938-0260 [email protected]
